Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Rheumatoid Arthritis with Inadequate Response to Methotrexate (RA-BALANCE)
NCT02265705Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2014
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Oct 2014; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02265705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265705.